Investing.com - BioNTech (NASDAQ: BNTX) reported third quarter EPS of €0.67, €0.05 better than the analyst estimate of €0.62. Revenue for the quarter came in at €895.3M versus the consensus estimate of €837.61M.
BioNTech's stock price closed at €95.78. It is down -10.06% in the last 3 months and down -40.41% in the last 12 months.
BioNTech saw 3 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See BioNTech's stock price’s past reactions to earnings here.
According to InvestingPro, BioNTech's Financial Health score is "excellent performance".
Check out BioNTech's recent earnings performance, and BioNTech's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in BNTX right now?
With BNTX making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed BNTX alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including BNTX, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is BNTX poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now